One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Neuro-Advocacy—Professionalism in Action
Barbara S. Giesser, MD1; Marisa Kanof, JD, MPP2
doi : 10.1001/jamaneurol.2021.4049
JAMA Neurol. 2022;79(1):7-8
On Cave Paintings and Shallow Waters—The Case for Advancing Spinal Cord Imaging in Multiple Sclerosis
Stephen Krieger, MD1
doi : 10.1001/jamaneurol.2021.4245
JAMA Neurol. 2022;79(1):9-10
The Promise and Peril of the Patient Portal
Kristen M. Coppola, PhD1
doi : 10.1001/jamaneurol.2021.4453
JAMA Neurol. 2022;79(1):11-12
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
Stephen Salloway, MD1; Spyros Chalkias, MD2; Frederik Barkhof, MD3,4; Patrick Burkett, MD2; Jerome Barakos, MD5,6; Derk Purcell, MD5,6; Joyce Suhy, PhD6; Fiona Forrestal, MSc2; Ying Tian, PhD2; Kimberly Umans, PhD2; Guanfang Wang, PhD7; Priya Singhal, MD2; Samantha Budd Haeberlein, PhD2; Karen Smirnakis, MD2
doi : 10.1001/jamaneurol.2021.4161
JAMA Neurol. 2022;79(1):13-21
The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-? (A?)–targeting monoclonal antibody, in patients with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia.
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion
Thanh N. Nguyen, MD1,2; Mohamad Abdalkader, MD2; Simon Nagel, MD3; Muhammad M. Qureshi, MPH2,4; Marc Ribo, MD, PhD5; Francois Caparros, MD6; Diogo C. Haussen, MD7; Mahmoud H. Mohammaden, MD, MSc7; Sunil A. Sheth, MD8; Santiago Ortega-Gutierrez, MD, MSc9; James E. Siegler, MD10; Syed Zaidi, MD11; Marta Olive-Gadea, MD5; Hilde Henon, MD, PhD6; Markus A. Möhlenbruch, MD12; Alicia C. Castonguay, PhD11; Stefania Nannoni, MD13; Johannes Kaesmacher, MD14,15; Ajit S. Puri, MD16; Fatih Seker, MD12; Mudassir Farooqui, MD, MPH9; Sergio Salazar-Marioni, MD8; Anna L. Kuhn, MD16; Artem Kaliaev, MD2; Behzad Farzin, MD17; William Boisseau, MD17; Hesham E. Masoud, MD18; Carlos Ynigo Lopez, MD18; Ameena Rana, MD10; Samer Abdul Kareem, MD19; Anvitha Sathya1; Piers Klein2; Mohammad W. Kassem, MD, MBA19; Peter A. Ringleb, MD3; Charlotte Cordonnier, MD, PhD6; Jan Gralla, MD14; Urs Fischer, MD, MSc20,21; Patrik Michel, MD13; Tudor G. Jovin, MD10; Jean Raymond, MD17; Osama O. Zaidat, MD, MS19; Raul G. Nogueira, MD7
doi : 10.1001/jamaneurol.2021.4082
JAMA Neurol. 2022;79(1):22-31
Advanced imaging for patient selection in mechanical thrombectomy is not widely available.
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies
Maria C. Gonzalez, MD1,2,3; Nicholas J. Ashton, PhD4,5; Bárbara Fernandes Gomes, MSc4; Diego Alejandro Tovar-Rios, MSc3; Frédéric Blanc, MD6; Thomas K. Karikari, PhD4; Brit Mollenhauer, MD7; Andrea Pilotto, MD8; Afina Lemstra, MD9; Claire Paquet, MD10; Carla Abdelnour, MD11; Milica G. Kramberger, MD12; Laura Bonanni, MD13; Rik Vandenberghe, MD14; Abdul Hye, PhD5; Kaj Blennow, MD4; Henrik Zetterberg, MD15,16,17,18,19; Dag Aarsland, MD3,5; for the European–Dementia With Lewy Bodies (E-DLB) Consortium
doi : 10.1001/jamaneurol.2021.4222
JAMA Neurol. 2022;79(1):32-37
Plasma phosphorylated tau (p-tau) has proven to be an accurate biomarker for Alzheimer disease (AD) pathologic characteristics, offering a less expensive and less invasive alternative to cerebrospinal fluid (CSF) and positron emission tomography biomarkers for amyloid-? and tau. Alzheimer disease comorbid pathologic characteristics are common and are associated with more rapid cognitive decline in patients with dementia with Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility in assessing cognitive impairment in individuals with this disorder.
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death
Juan María Sanchez-Caro, MD1; Iñigo de Lorenzo Martínez de Ubago, MD1; Elena de Celis Ruiz, MD1; Ainara Barguilla Arribas, MD2; Lionel Calviere, MD3,4; Nicolas Raposo, MD, PhD3,4; Rafael Galiano Blancart, MD5; Blanca Fuentes, MD, PhD1; Exuperio Diez-Tejedor, MD, PhD1; Jorge Rodriguez-Pardo, MD, PhD1
doi : 10.1001/jamaneurol.2021.3989
JAMA Neurol. 2022;79(1):38-47
Transient focal neurological episodes (TFNEs) are a frequently overlooked presentation of cerebral amyloid angiopathy (CAA), a condition with prognostic implications that are still not well described.
Research Criteria for the Behavioral Variant of Alzheimer Disease
Rik Ossenkoppele, PhD1,2; Ellen H. Singleton, MS1; Colin Groot, PhD1; Anke A. Dijkstra, PhD3; Willem S. Eikelboom, MS4; William W. Seeley, MD5; Bruce Miller, MD5; Robert Jr Laforce, MD, PhD6; Philip Scheltens, MD, PhD1; Janne M. Papma, PhD4; Gil D. Rabinovici, MD5,7,8,9; Yolande A. L. Pijnenburg, MD, PhD1
doi : 10.1001/jamaneurol.2021.4417
JAMA Neurol. 2022;79(1):48-60
The behavioral variant of Alzheimer disease (bvAD) is characterized by early and predominant behavioral deficits caused by AD pathology. This AD phenotype is insufficiently understood and lacks standardized clinical criteria, limiting reliability and reproducibility of diagnosis and scientific reporting.
Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes
Kazunori Toyoda, MD, PhD1; Sohei Yoshimura, MD, PhD1; Michikazu Nakai, PhD2; Masatoshi Koga, MD, PhD1; Yusuke Sasahara, PhD2; Kazutaka Sonoda, MD3; Kenji Kamiyama, MD, PhD4; Yukako Yazawa, MD5; Sanami Kawada, MD6; Masahiro Sasaki, MD, PhD7; Tadashi Terasaki, MD, PhD8; Kaori Miwa, MD, PhD1; Junpei Koge, MD1; Akiko Ishigami, MD1; Shinichi Wada, MD, PhD2; Yoshitaka Iwanaga, MD, PhD2; Yoshihiro Miyamoto, MD, PhD2; Kazuo Minematsu, MD, PhD9; Shotai Kobayashi, MD, PhD10; for the Japan Stroke Data Bank Investigators
doi : 10.1001/jamaneurol.2021.4346
JAMA Neurol. 2022;79(1):61-69
Whether recent changes in demographic characteristics and therapeutic technologies have altered stroke outcomes remains unknown.
Development and Validation of the 5-SENSE Score to Predict Focality of the Seizure-Onset Zone as Assessed by Stereoelectroencephalography
Alexandra Astner-Rohracher, MD1,2; Georg Zimmermann, PhD3; Tamir Avigdor, MSc1; Chifaou Abdallah, MD1; Nirav Barot, MD4; Milan Brázdil, MD, PhD5; Irena Doležalová, MD, PhD5; Jean Gotman, PhD1; Jeffery Alan Hall, MD1; Kirsten Ikeda, MD6; Philippe Kahane, MD, PhD7; Gudrun Kalss, MD2; Vasileios Kokkinos, PhD8; Markus Leitinger, MD2; Ioana Mindruta, MD, PhD9; Lorella Minotti, MD7; Mary Margaret Mizera, BSN10; Irina Oane, MD, PhD9; Mark Richardson, MD, PhD8; Stephan U. Schuele, MD10; Eugen Trinka, MD2,11,12,13; Alexandra Urban, MD4; Benjamin Whatley, MD6; François Dubeau, MD1; Birgit Frauscher, MD, PD1
doi : 10.1001/jamaneurol.2021.4405
JAMA Neurol. 2022;79(1):70-79
Stereoelectroencephalography (SEEG) has become the criterion standard in case of inconclusive noninvasive presurgical epilepsy workup. However, up to 40% of patients are subsequently not offered surgery because the seizure-onset zone is less focal than expected or cannot be identified.
Bilateral Trigeminal Myokymia in Chronic Inflammatory Demyelinating Polyneuropathy With Systemic Lupus Erythematosus–Sjögren Overlap Syndrome
Arpan Dutta, MBBS, MD1; Subhadeep Gupta, MBBS, MD1; Biman Kanti Ray, MBBS, MD, DM1
doi : 10.1001/jamaneurol.2021.4069
JAMA Neurol. 2022;79(1):80-81
Linear Radial Brainstem Enhancement in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy
Ario Mirian, MD, MSc1; Manas Sharma, MD2; Adrian Budhram, MD1,3
doi : 10.1001/jamaneurol.2021.4054
JAMA Neurol. 2022;79(1):82-83
Acute Myelopathy in a Man With Cutaneous Papules
Shermyn Neo, MBBS1; Chee Seng Sim, MBBS2; Chia Chun Ang, MBBS3
doi : 10.1001/jamaneurol.2021.4194
JAMA Neurol. 2022;79(1):84-85
Susceptibility-Weighted Imaging of Intravascular Lymphoma of the Central Nervous System
Megan B. Richie, MD1; Elan L. Guterman, MD1; Maulik P. Shah, MD1; Soonmee Cha, MD2
doi : 10.1001/jamaneurol.2021.4391
JAMA Neurol. 2022;79(1):86-87
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab
Jacob N. Hall, MD1; Elizabeth Mormino, PhD2; Amanda Ng, MA2; Athanasia Boumis, BA3; Jennifer L. Gaudioso, BA4; Guido A. Davidzon, MD5; Sharon J. Sha, MD2
doi : 10.1001/jamaneurol.2021.3933
JAMA Neurol. 2022;79(1):87-89
Concerns Remain Regarding Ambient NO2 Exposure and the Risk of Parkinson Disease
Wenming Shi, PhD1; Lena Kan, PhD2; Yongzhen Li, PhD3,4,5
doi : 10.1001/jamaneurol.2021.4103
JAMA Neurol. 2022;79(1):89
Concerns Remain Regarding Ambient NO2 Exposure and the Risk of Parkinson Disease—Reply
Sungyang Jo, MD1; Ye-Jee Kim, PhD2; Sun Ju Chung, MD, PhD1
doi : 10.1001/jamaneurol.2021.4106
JAMA Neurol. 2022;79(1):89-90
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures
John Crawford, MD, MS1,2; Jeffrey Gold, MD, PhD1,2; Richard Haas, MB, BChir, MRCP1,2
doi : 10.1001/jamaneurol.2021.4109
JAMA Neurol. 2022;79(1):90-91
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures—Reply
Hannah C. Glass, MDCM, MAS1,2,3; Renée A. Shellhaas, MD, MS4
doi : 10.1001/jamaneurol.2021.4112
JAMA Neurol. 2022;79(1):91-92
Unconvincing Evidence of SARS-CoV-2–Associated Myositis in Autopsied Muscles
Marinos C. Dalakas, MD1,2
doi : 10.1001/jamaneurol.2021.4336
JAMA Neurol. 2022;79(1):92
Unconvincing Evidence of SARS-CoV-2–Associated Myositis in Autopsied Muscles—Reply
Tom Aschman, MD1; Hans-Hilmar Goebel, MD1; Werner Peter Stenzel, MD1
doi : 10.1001/jamaneurol.2021.4339
JAMA Neurol. 2022;79(1):92-93
